Do analysts prefer NNVC or RFAI?

NanoViricides currently has a consensus target price of $6.00, suggesting a potential upside of 354.55%. Given NanoViricides' stronger consensus rating and higher possible upside, analysts clearly believe NanoViricides is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, NNVC or RFAI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.40 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Is NNVC or RFAI more profitable?

RF Acquisition Corp II's return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% RF Acquisition Corp II N/A N/A N/A

Is VTVT or NNVC more profitable?

vTv Therapeutics' return on equity of -6.27% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A -6.27% -5.06% NanoViricides N/A -87.90% -78.69%

Do analysts recommend NNVC or BGM?

NanoViricides presently has a consensus target price of $6.00, suggesting a potential upside of 354.55%. Given NanoViricides' stronger consensus rating and higher possible upside, equities analysts plainly believe NanoViricides is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, NNVC or BGM?

NanoViricides has higher earnings, but lower revenue than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.40 N/A BGM Group $37.92M 3.37 -$19.94M N/A N/A

Is NNVC or BGM more profitable?

BGM Group's return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% BGM Group N/A N/A N/A

Is NNVC or UNCY more profitable?

NanoViricides' return on equity of -87.90% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Unicycive Therapeutics N/A -91.50% -61.47%

NanoViricides (NNVC) Competitors

$1.32 -0.01 (-0.38%)

As of 02:29 PM Eastern

Compare

NNVC vs. RFAI, NRXP, VTVT, BGM, and UNCY

Should you buy NanoViricides stock or one of its competitors? NanoViricides's main competitors and comparable companies include RF Acquisition Corp II (RFAI), NRx Pharmaceuticals (NRXP), vTv Therapeutics (VTVT), BGM Group (BGM), and Unicycive Therapeutics (UNCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NanoViricides compare to RF Acquisition Corp II?

NanoViricides (NYSE:NNVC) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.40	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

NanoViricides currently has a consensus target price of $6.00, suggesting a potential upside of 354.55%. Given NanoViricides' stronger consensus rating and higher possible upside, analysts clearly believe NanoViricides is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

RF Acquisition Corp II's return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
RF Acquisition Corp II	N/A	N/A	N/A

NanoViricides has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

10.3% of NanoViricides shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, RF Acquisition Corp II had 5 more articles in the media than NanoViricides. MarketBeat recorded 5 mentions for RF Acquisition Corp II and 0 mentions for NanoViricides. RF Acquisition Corp II's average media sentiment score of 0.51 beat NanoViricides' score of 0.25 indicating that RF Acquisition Corp II is being referred to more favorably in the news media.

Company	Overall Sentiment
NanoViricides	Neutral
RF Acquisition Corp II	Positive

Summary

NanoViricides and RF Acquisition Corp II tied by winning 5 of the 10 factors compared between the two stocks.

How does NanoViricides compare to NRx Pharmaceuticals?

NanoViricides (NYSE:NNVC) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

NanoViricides has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market.

NanoViricides presently has a consensus price target of $6.00, suggesting a potential upside of 354.55%. NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 1,177.78%. Given NRx Pharmaceuticals' higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

NanoViricides has higher earnings, but lower revenue than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.40	N/A
NRx Pharmaceuticals	$1.23M	95.05	-$28.62M	-$0.55	N/A

NanoViricides has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 3.6% of NanoViricides shares are held by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, NRx Pharmaceuticals had 1 more articles in the media than NanoViricides. MarketBeat recorded 1 mentions for NRx Pharmaceuticals and 0 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.25 beat NRx Pharmaceuticals' score of -0.26 indicating that NanoViricides is being referred to more favorably in the media.

Company	Overall Sentiment
NanoViricides	Neutral
NRx Pharmaceuticals	Neutral

Summary

NRx Pharmaceuticals beats NanoViricides on 8 of the 15 factors compared between the two stocks.

How does NanoViricides compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and NanoViricides (NYSE:NNVC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

vTv Therapeutics' return on equity of -6.27% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
NanoViricides	N/A	-87.90%	-78.69%

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 3.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

NanoViricides has lower revenue, but higher earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	109.05	-$26.97M	-$1.06	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.40	N/A

In the previous week, vTv Therapeutics had 9 more articles in the media than NanoViricides. MarketBeat recorded 9 mentions for vTv Therapeutics and 0 mentions for NanoViricides. vTv Therapeutics' average media sentiment score of 0.27 beat NanoViricides' score of 0.25 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
vTv Therapeutics	Neutral
NanoViricides	Neutral

vTv Therapeutics presently has a consensus target price of $55.83, suggesting a potential upside of 97.78%. NanoViricides has a consensus target price of $6.00, suggesting a potential upside of 354.55%. Given NanoViricides' stronger consensus rating and higher possible upside, analysts clearly believe NanoViricides is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

vTv Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Summary

vTv Therapeutics beats NanoViricides on 9 of the 15 factors compared between the two stocks.

How does NanoViricides compare to BGM Group?

NanoViricides (NYSE:NNVC) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

BGM Group's return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
BGM Group	N/A	N/A	N/A

In the previous week, BGM Group had 2 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for BGM Group and 0 mentions for NanoViricides. BGM Group's average media sentiment score of 0.39 beat NanoViricides' score of 0.25 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
NanoViricides	Neutral
BGM Group	Neutral

NanoViricides has higher earnings, but lower revenue than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.40	N/A
BGM Group	$37.92M	3.37	-$19.94M	N/A	N/A

10.3% of NanoViricides shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by company insiders. Comparatively, 58.7% of BGM Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NanoViricides has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

NanoViricides presently has a consensus target price of $6.00, suggesting a potential upside of 354.55%. Given NanoViricides' stronger consensus rating and higher possible upside, equities analysts plainly believe NanoViricides is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BGM Group beats NanoViricides on 7 of the 12 factors compared between the two stocks.

How does NanoViricides compare to Unicycive Therapeutics?

NanoViricides (NYSE:NNVC) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

NanoViricides currently has a consensus price target of $6.00, indicating a potential upside of 354.55%. Unicycive Therapeutics has a consensus price target of $18.25, indicating a potential upside of 389.28%. Given Unicycive Therapeutics' higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Unicycive Therapeutics had 11 more articles in the media than NanoViricides. MarketBeat recorded 11 mentions for Unicycive Therapeutics and 0 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.25 beat Unicycive Therapeutics' score of 0.06 indicating that NanoViricides is being referred to more favorably in the media.

Company	Overall Sentiment
NanoViricides	Neutral
Unicycive Therapeutics	Neutral

NanoViricides' return on equity of -87.90% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

NanoViricides has higher earnings, but lower revenue than Unicycive Therapeutics. NanoViricides is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.40	N/A
Unicycive Therapeutics	$680K	152.77	-$26.56M	-$1.75	N/A

NanoViricides has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market.

Summary

Unicycive Therapeutics beats NanoViricides on 8 of the 14 factors compared between the two stocks.

Get NanoViricides News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNVC vs. The Competition

Export

Metric	NanoViricides	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$33.69M	$12.42B	$7.27B	$22.90B
Dividend Yield	N/A	2.63%	2.51%	3.72%
P/E Ratio	-1.83	807.81	275.40	28.08
Price / Sales	N/A	748.45	562.29	21.03
Price / Cash	N/A	86.65	77.16	37.05
Price / Book	2.00	9.21	10.55	4.66
Net Income	-$8.29M	$2.84B	$3.50B	$1.07B
7 Day Performance	-8.33%	-4.00%	-3.92%	-0.88%
1 Month Performance	25.71%	-8.07%	-8.30%	-4.51%
1 Year Performance	-2.22%	-5.86%	2.35%	5.30%

NanoViricides Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNVC NanoViricides	1.7069 of 5 stars	$1.32 -0.4%	$6.00 +356.3%	-2.9%	$33.69M	N/A	N/A	7
RFAI RF Acquisition Corp II	1.7506 of 5 stars	$38.60 +2.8%	N/A	+264.3%	$131.89M	N/A	N/A	2	Short Interest Decrease Gap Down
NRXP NRx Pharmaceuticals	1.9027 of 5 stars	$2.94 +2.4%	$34.50 +1,073.5%	-13.5%	$124.26M	$1.23M	N/A	29
VTVT vTv Therapeutics	3.1466 of 5 stars	$30.03 -1.0%	$55.83 +85.9%	+29.4%	$119.47M	$1.02M	N/A	26	Analyst Forecast
BGM BGM Group	0.5901 of 5 stars	$9.65 +3.2%	N/A	-96.5%	$118.63M	$37.92M	N/A	471	Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NNVC) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NanoViricides (NNVC) Competitors

NNVC vs. RFAI, NRXP, VTVT, BGM, and UNCY

How does NanoViricides compare to RF Acquisition Corp II?

Summary

How does NanoViricides compare to NRx Pharmaceuticals?

Summary

How does NanoViricides compare to vTv Therapeutics?

Summary

How does NanoViricides compare to BGM Group?

Summary

How does NanoViricides compare to Unicycive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NanoViricides (NNVC) Competitors

NNVC vs. RFAI, NRXP, VTVT, BGM, and UNCY

How does NanoViricides compare to RF Acquisition Corp II?

Which has stronger valuation & earnings, NNVC or RFAI?

Do analysts prefer NNVC or RFAI?

Is NNVC or RFAI more profitable?

Which has more volatility & risk, NNVC or RFAI?

Do insiders & institutionals hold more shares of NNVC or RFAI?

Does the media prefer NNVC or RFAI?

Summary

How does NanoViricides compare to NRx Pharmaceuticals?

Which has more volatility and risk, NNVC or NRXP?

Do analysts prefer NNVC or NRXP?

Which has preferable earnings & valuation, NNVC or NRXP?

Is NNVC or NRXP more profitable?

Do insiders & institutionals believe in NNVC or NRXP?

Does the media prefer NNVC or NRXP?

Summary

How does NanoViricides compare to vTv Therapeutics?

Is VTVT or NNVC more profitable?

Do insiders and institutionals hold more shares of VTVT or NNVC?

Which has higher earnings & valuation, VTVT or NNVC?

Does the media favor VTVT or NNVC?

Do analysts rate VTVT or NNVC?

Which has more volatility & risk, VTVT or NNVC?

Summary

How does NanoViricides compare to BGM Group?

Is NNVC or BGM more profitable?

Does the media prefer NNVC or BGM?

Which has better valuation and earnings, NNVC or BGM?

Do institutionals & insiders hold more shares of NNVC or BGM?

Which has more volatility & risk, NNVC or BGM?

Do analysts recommend NNVC or BGM?

Summary

How does NanoViricides compare to Unicycive Therapeutics?

Do analysts rate NNVC or UNCY?

Do institutionals & insiders believe in NNVC or UNCY?

Does the media prefer NNVC or UNCY?

Is NNVC or UNCY more profitable?

Which has preferable earnings and valuation, NNVC or UNCY?

Which has more volatility and risk, NNVC or UNCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools